The Cannigma

APRIL 12, 2023

CBN has made headlines and claimed shelf space as the next best cannabinoid for sleep. In 2021, MoreBetter used its web-based software to track over 350 people using a CBN tincture from CBDistillery. Over 31 days, 388 people reported on their sleep before and after trialing the CBN product. Back to our study.

Sleep 137

Sleep Data Tincture Research and Development 137

Cannabis Law Report

AUGUST 10, 2021

CSE: LOAN ) (FSE: O3X) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“Global” or the “Company”) is pleased to announce the signing of a definitive agreement on August 6th 2021 memorializing the Global Wellness Strategies , Inc. binding letter of intent signed on July 12th 2021 to purchase certain assets of Cannvalate Pty Ltd. (“CV”)

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.) 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Cannabinoids 40

Cannabinoids Clinical Trials Research and Development Supply Chain 40

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. July 28, 2021 07:00 ET | Source: KetamineOne Capital Limite.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 40

Clinical Trials Data Patients THC 40

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

The Cannigma

JUNE 23, 2022

While CBG (cannabigerol) has been hailed ‘the mother of all cannabinoids,’ it’s time to reveal the true heir to the throne – cannabigerolic acid, or CBGA. This cannabinoid has only recently been studied, and future studies will certainly divulge its exact importance. What is the difference between CBG and CBGa? What does CBGA do?

Cannabinoids 126

Cannabinoids Research and Development Clinical Trials Extraction 126

Cannabis Law Report

AUGUST 2, 2021

2, 2021 /PRNewswire/ — SciSparc Ltd. OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

MedicalJane

OCTOBER 3, 2019

The United States Department of Defense and GW Pharmaceuticals are collaborating on a new clinical trial at the Montefiore Medical Center in New York. The study examines the effect of the cannabinoid Cannabidivarin, more commonly referred to as CBDV , on irritability and repetitive behaviors in children with autism spectrum disorder.

Clinical Trials 74

Clinical Trials Epilepsy Pharmaceutical Treatment 74

Cannabis Law Report

JUNE 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. The May 4, 2021 guidance for revenue was in the range of $2.5 – $2.7 That has been increased as of June 17, 2021, to a range of $3.0

Pharmaceutical 83

Pharmaceutical Clinical Trials Therapy Programs 83

Cannabis Law Report

JULY 26, 2021

SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has appointed Praveen Tyle, Ph.D., About Skye Bioscience.

Research and Development 105

Research and Development Clinical Trials Pharmaceutical Cannabinoids 105

Cannabis Law Report

AUGUST 13, 2021

Instead, it is hypothesised that SalA indirectly influences the cannabinoid system, as well as being an allosteric modulator of the µ opioid receptor. Clinically, there are published reports of the potential benefits of Salvia divinorum in the treatment of TRD. BERLIN, Aug.

Conditions 105

Conditions Research and Development Clinical Trials Treatment 105

Cannabis Law Report

JUNE 17, 2021

VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. Brains” or the “Company”) is pleased to announce the completion of a USD $31.9

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

TheAnswerPage

JANUARY 11, 2022

and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ In addition, if clinicians are not well informed about the health effects of cannabinoid-based products, clinicians will not be able to optimally treat their patients. million medical marijuana patients nationwide.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JULY 8, 2021

Seeks To Identify Novel Cannabinoids For Therapeutic Use. The Company expects to finalize the agreement with the research institute and commence studies by Fall 2021. This safety data will support the ensuing preclinical trials in humans to explore the efficacy of the cannabinoids. CHARLOTTE, N.C.–(BUSINESS

Research and Development 85

Research and Development Pets Cannabinoids eCommerce 85

LifeCannMD

MAY 27, 2025

What really opened my eyes was this study that came out in 2021. ” His research, published in Cannabis and Cannabinoid Research , demonstrates that low doses of THC can actually produce opposite effects from high doses. With cannabis, we’re talking about tiny amounts maybe 1 to 5 milligrams of THC, sometimes even less.

Microdosing 52

Microdosing Research and Development Sleep Chronic Pain 52

Cannabis Law Report

JUNE 30, 2021

LONDON–(BUSINESS WIRE)– Fourfive , the CBD and nutrition brand loved by athletes and those leading an active lifestyle, today called on the UK’s sports governing bodies to stop sitting if on the fence and conduct clinical trials into the effectiveness of CBD and medicinal cannabis in professional sport.

Medicine 75

Medicine Clinical Trials CBD Sleep 75

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. ” The study began last April, and the clinical trial plans to document results on 100 participants, ages 5-18, for the duration of 84 days (12 weeks) of treatments through June 2021.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

Cannabis Law Report

NOVEMBER 12, 2021

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. and Arjun Chanmugam, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

OCTOBER 22, 2021

The “Medical Marijuana – Cannabidiol – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering. Medical Marijuana – Cannabidiol – Pipeline Insight, 2021” report provides comprehensive insights for about 25+ companies and 50+ pipeline drugs in Medical Marijuana – Cannabidiol pipeline landscape.

Research and Development 52

Research and Development Pharmaceutical Marijuana Chronic Pain 52

TheAnswerPage

JANUARY 21, 2021

Researchers have evaluated the anti-neoplastic (anti-cancer) effects of cannabinoids. Over the past two decades, PRECLINICAL data indicate that THC, CBD, as well as some synthetic cannabinoids induce apoptosis of cancer cells and inhibit tumor proliferation, metastasis, and angiogenesis. What have the results indicated? See Answer.

Clinical Trials 40

Clinical Trials Data Cannabinoids THC 40

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Presentations at ASN Kidney Week 2021, November 4-7, 2021.

Clinical Trials 40

Clinical Trials Research and Development Data Patients 40

Veriheal

SEPTEMBER 18, 2020

million of NWS Health funding for their Cannabinoid Therapeutics and Brain and Mind Centre to see if cannabidiol can be that effective treatment for spinal cord injury. The professor has teamed up with cannabinoid, neuroinflammation, and spinal cord injury experts in order to successfully pull off this study. Sachin Shetty.

Treatment 98

Treatment Chronic Pain CBD Research and Development 98

TheAnswerPage

MAY 29, 2021

A common adverse effect of chronic recreational marijuana use is cannabinoid hyperemesis syndrome. In fact, cannabinoid hyperemesis syndrome is a near daily diagnosis in many Canadian emergency departments. Anecdotal evidence supports the use of haloperidol to treat cannabinoid hyperemesis syndrome. mg/kg or 0.1 Ruberto, A.,

Clinical Trials 40

Clinical Trials Cannabinoids Treatment Recreational 40

The Cannigma

AUGUST 14, 2022

There is certainly some evidence that cannabis may be helpful with increasing focus, in the right dose with the right terpenes and cannabinoids. The short answer is maybe – it depends on several factors, including the cannabinoids and terpenes in your weed, as well as how much you consume. It starts with the right cannabinoids.

Terpenes 128

Terpenes Strains THC Oil 128

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 85

Clinical Trials Research and Development Therapy Conditions 85

Cannabis Law Report

SEPTEMBER 22, 2021

Oxford Cannabinoid Technologies Holdings plc. . Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

JANUARY 27, 2022

The majority of industry-sponsored drugs in active clinical development for FXS are in Phase II, with two drugs in Phase III. The distribution of clinical trials across Phase I-IV indicates that the majority of trials for FXS have been in the early and midphases of development, with 77% of trials in Phase I-II, and only 23% in Phase III-IV.

Clinical Trials 40

Clinical Trials Therapy Cannabinoids Topical 40

Cannabis Law Report

DECEMBER 1, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. Date: December 2, 2021. Dates: December 8-9, 2021. Registration: Click here.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Therapy 40

Healer

DECEMBER 17, 2021

November 5, 2021. Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Most of the clinically relevant interactions of CBD with other drugs are related to competition in the liver’s detoxification pathways. 2021): 525-533.

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. During the six months ended September 30, 2021, the Company raised approximately $4.1 million for the three months ended September 30, 2021, from approximately $1.48

Clinical Trials 40

Clinical Trials Research and Development Data Business 40

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). What are the common adverse events noted in clinical trials examining the efficacy of cannabinoids for ASD? 17 Aug 2021. Fletcher S. Fletcher S. See the Answer.

Clinical Trials 40

Clinical Trials Events Therapy Sleep 40

Cannabis Law Report

JANUARY 14, 2022

Right-to-try aims to allow patients who have been diagnosed with life-threatening diseases or conditions who have tried all approved treatment options and who are unable to participate in a clinical trial to access certain unapproved treatments. Right-to-try permits those patients to have access to investigational drugs.

Treatment 52

Treatment Access Clinical Trials Patients 52

Cannabis Law Report

DECEMBER 7, 2021

Scientific Reports volume 11 , Article number: 23462 ( 2021 ) Cite this article. Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Metrics details. Introduction.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

MAY 10, 2022

Medicinal cannabis products such as capsules, creams, oils, lozenges, sprays and granulated flowers were approved for prescription 159,665 times between the start of Australia’s medicinal cannabis program in February 2016 and September 2021, research led by the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics shows.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

OCTOBER 5, 2021

is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. Rex Merchant.

Pharmaceutical 40

Pharmaceutical Clinical Trials Cannabinoids Events 40